Immunomedics Inc. (IMMU)

Trade IMMU now with
5/21/2018 8:10:40 AM Immunomedics Submits BLA For Sacituzumab Govitecan To FDA
4/9/2018 8:05:14 AM Immunomedics Appoints Robert Iannone Head Of Research & Development And Chief Medical Officer
1/8/2018 8:37:02 AM Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln
9/15/2017 8:02:50 AM Immunomedics Announces Agreements To Exchange About $80.0 Mln Of 4.75% Convertible Senior Notes Due 2020
9/11/2017 7:10:12 AM Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132)
8/21/2017 8:20:10 AM Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130)
5/12/2017 7:05:31 AM Company Spotlight: Immunomedics
5/5/2017 8:49:20 AM Immunomedics, Seattle Genetics Reach Mutual Agreement To Dissolve Exclusive Global Licensing Agreement